# Anlotinib Combined With Dose-dense Temozolomide for the First Recurrent or Progressive Glioblastoma After STUPP Regimen

> **NCT04547855** · PHASE2 · UNKNOWN · sponsor: **Yonggao Mou** · enrollment: 54 (estimated)

## Conditions studied

- Glioblastoma

## Interventions

- **DRUG:** anlotinib combined with dose-dense temozolomide

## Key facts

- **NCT ID:** NCT04547855
- **Lead sponsor:** Yonggao Mou
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-09-11
- **Primary completion:** 2022-09-11
- **Final completion:** 2023-03-11
- **Target enrollment:** 54 (ESTIMATED)
- **Last updated:** 2020-09-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04547855

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04547855, "Anlotinib Combined With Dose-dense Temozolomide for the First Recurrent or Progressive Glioblastoma After STUPP Regimen". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04547855. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*